ReviewCurrent diabetes reports2020
Dyslipidemia in Pediatric Type 2 Diabetes Mellitus.
Review in Current diabetes reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 65 citations in OpenAlex.
- Diabetic Dyslipidemia and Its Determinants Among People With Diabetes in South Africa: Protocol for a Systematic Review and Meta-Analysis.JMIR research protocols · 2026Article
- Dyslipidemia in children with type 1 diabetes across age groups in Southern Iran: is it time to rethink guidelines?BMC pediatrics · 2026Article
- 2025 Egyptian guidelines for the management of dyslipidemia.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Review
- A Systematic Review and Meta-Analysis of Efficacy and Safety of Liraglutide in Patients with Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Observational
- Astaxanthin attenuates DNA fragmentation and cognitive decline in type 2 diabetic rats.Scientific reports · 2025Article
- Oxidative Stress and Endothelial Dysfunction: The Pathogenesis of Pediatric Hypertension.International journal of molecular sciences · 2025Review
- Targeting Mitochondrial Dysfunction to Prevent Endothelial Dysfunction and Atherosclerosis in Diabetes: Focus on the Novel Uncoupler BAM15.International journal of molecular sciences · 2025Review
- Accounting for the impact of rare variants on causal inference with RARE: a novel multivariable Mendelian randomization method.Briefings in bioinformatics · 2025Article
- [Early Predictors for Hypertriglyceridemic Acute Pancreatitis].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025Review
- Molecular Mechanism of Vine Tea Dihydromyricetin Extract on Alleviating Glucolipid Metabolism Disorder inInternational journal of molecular sciences · 2025Article
- Endocrine consequences of childhood obesity: a narrative review.Frontiers in endocrinology · 2025Review
- NPC1L1 rs217434 A > G as a Novel Single Nucleotide Polymorphism Related to Dyslipidemia in a Korean Population.Biochemical genetics · 2024Article
- Strategies for Cardiovascular Disease Prevention in Type 1 Diabetes: A Comprehensive Review.Cureus · 2024Review
- Exploring determinants of sex and family history-based disparity in type 2 diabetes mellitus prevalence among clinical patients.BMC public health · 2024Article
- Factors affecting weight management in overweight or obese diabetic patients: the 2018-2021 Korea national health and nutrition examination survey.Physical activity and nutrition · 2024Article
- Insulin Resistance in Pediatric Obesity: From Mechanisms to Treatment Strategies.Pediatric diabetes · 2024Review
- Reassessing type 2 diabetes in adolescents and its management strategies based on insulin resistance.Frontiers in endocrinology · 2024Review
- A decreased level of high-density lipoprotein is a possible risk factor for type 2 diabetes mellitus: A review.Health science reports · 2023Article
- Combination of Shengmai San and Radix puerariae ameliorates depression-like symptoms in diabetic rats at the nexus of PI3K/BDNF/SYN protein expression.Animal models and experimental medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewCardiovascular (CV) disease is a major cause of mortality in type 2 diabetes mellitus (T2D). Dyslipidemia is prevalent in children with T2D and is a known risk factor for CVD. In this review, we critically examine the epidemiology, pathophysiology, and recommendations for dyslipidemia management in pediatric T2D. RECENT
findingsDyslipidemia is multifactorial and related to poor glycemic control, insulin resistance, inflammation, and genetic susceptibility. Current guidelines recommend lipid screening after achieving glycemic control and annually thereafter. The desired lipid goals are low-density lipoprotein cholesterol (LDL-C) < 100 mg/dL, high-density lipoprotein cholesterol (HDL-C) > 35 mg/dL, and triglycerides (TG) < 150 mg/dL. If LDL-C remains > 130 mg/dL after 6 months, statins are recommended with a treatment goal of < 100 mg/dL. If fasting TG are > 400 mg/dL or non-fasting TG are > 1000 mg/dL, fibrates are recommended. Although abnormal levels of atherogenic TG-rich lipoproteins, apolipoprotein B, and non-HDL-C are commonly present in pediatric T2D, their measurement is not currently considered in risk assessment or management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.